MindMaze Therapeutics to Launch Tablet-Based MindMotion Lite by Year-End 2026
Geneva – September 19, 2026 -- MindMaze Therapeutics (SIX: MMTX) will launch MindMotion Lite by the end of 2026, a tablet-based neurorehabilitation device designed to cut home deployment costs and expand access to intensive stroke and neurological therapy outside clinical settings.
Tablet format replaces bulky hardware for home use
MindMotion Lite delivers the full range of neurotherapeutic activities currently available on the company's MindMotion GO system through a tablet interface, reducing the hardware footprint required for in-home deployment. The device retains full-body rehabilitation training capacity while streamlining the user experience for patients managing therapy at home. It also supports teleconsultation and remote management, allowing clinicians to monitor and adjust treatment plans as patients continue therapy beyond the clinic.